Visualize HL7 Example and Test Instances (vi7eti)

Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/

Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.

BACK TO LIST

Patient
Name:	Burns, Jonathan
DOB:	29-JAN-1981 (Age: 44)
Gender:	male
Address:	71 High Street BA22 5XY Ashington (United Kingdom)
ID:	1456-931853-9

Report
Date:	02-NOV-2021

Laboratory

Requested by
Yeovil District Hospital BA21 3 Yeovil (United Kingdom)

Specimen
Collected:	01-NOV-2021

This seems not to be an HL7 Europe Laboratory Report (type coding LOINC 11502-2)

Chemistry

Test	01 Nov 2021	Reference Range	Unit
Hemoglobin A1c/Hemoglobin.total in Blood	5.9	4 - 6	%
Glucose [Mass/volume] in Blood	85.6	70 - 99	mg/dL
Urea nitrogen [Mass/volume] in Blood	20.0	7 - 40	mg/dL
Creatinine [Mass/volume] in Blood	1.3	0.6 - 1.3	mg/dL
Calcium [Mass/volume] in Blood	9.6	8.5 - 10.5	mg/dL
Sodium [Moles/volume] in Blood	136.0	135 - 145	mmol/L
Potassium [Moles/volume] in Blood	4.0	3.5 - 5	mmol/L
Chloride [Moles/volume] in Blood	104.0	98 - 114	mmol/L
Carbon dioxide, total [Moles/volume] in Blood	26.0	22 - 29	mmol/L
Cholesterol [Mass/volume] in Serum or Plasma	281.1 H	0 - 200	mg/dL
Triglyceride [Mass/volume] in Serum or Plasma	145.8	40 - 150	mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay	190.0 H	0 - 100	mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma	61.9	40 - 100	mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows persistently elevated total and LDL cholesterol, indicating increased cardiovascular risk and need for lipid management. HbA1c is at the upper limit of normal but improved since 2019, suggesting better glycemic control. Renal function, electrolytes, and blood counts are within normal limits except for a previously low erythrocyte count and high platelet distribution width, which may warrant monitoring. Overall, main concerns are dyslipidemia and cardiovascular risk.

Conclusion and Recommendations based on this report and previous findings known to us

The patient shows persistently elevated total and LDL cholesterol, indicating increased cardiovascular risk and need for lipid management. HbA1c is at the upper limit of normal but improved since 2019, suggesting better glycemic control. Renal function, electrolytes, and blood counts are within normal limits except for a previously low erythrocyte count and high platelet distribution width, which may warrant monitoring. Overall, main concerns are dyslipidemia and cardiovascular risk.